A carregar...
Projeto de investigação
Innovative & personalized RNA-based therapies for rare diseases and development of models for their testing: application to Mucolipidosis II
Financiador
Autores
Publicações
Is Antisense Oligonucleotide-Mediated Exon Skipping a Potential Therapeutic Approach for Mucolipidosis II?
Publication . Gonçalves, Mariana; Moreira, Luciana; Encarnação, Marisa; Duarte, Ana Joana; Gaspar, Paulo; Santos, Juliana Inês; Coutinho Maria Francisca; Prata, Maria João; Omidi, Maryam; Pohl, Sandra; Silva, Frederico; Oliveira, Paula; Matos, Liliana; Alves, Sandra
Intridution: Mucolipidosis II (ML II) is a Lysosomal Storage Disorder caused by N-acetylglucosamine-1-phosphotransferase (GlcNAc-PT) deficiency, which impairs lysosomal hydrolases trafficking. Here, we explored an innovative therapeutic strategy based on the use of antisense oligonucleotides (ASOs) to promote targeted skipping of GNPTAB exon 19, which harbors c.3503_3504del, the most frequent disease-causing variant. Previously, in ML II patients’ fibroblasts, we tested ASOs to induce exon 19 skipping, successfully generating an in-frame mRNA1. Now, our aim is to determine if this in-frame transcript leads to increased GlcNAc-PT levels.
Methodology: First, the GlcNAc-PT activity was measured in fibroblasts, but activity levels were similar in ML II and control fibroblasts (treated/non-treated) showing that the assay is not proper to measure endogenous levels. To overcome this, we designed 3 constructs: a WT (full GNPTAB cDNA), a del_ex19 (without exon 19) and a mutant (with the mutation c.3503_3504del) that were transfected in HEK293T cells. Then GlcNAc-PT expression was analyzed by Western Blot (WB).
Also, we measured the activity of several hydrolases and evaluated the expression of α-galactosidase A (α-Gal) by WB after ASO treatment.
To further validate this therapy we also generated a novel GlcNAc-PT antibody in rabbits.
Results: Our results showed that HEK293T cells were able to express all the constructs. The WB of both WT and del_ex19 constructs showed bands corresponding to the α/β precursor. However, only the WT construct expressed the β-subunit, suggesting that there is no GlcNAc-PT activity in the absence of exon 19. As expected, in the delTC construct WB no α/β precursor band was detected.
We also observed a slight increase in the activity of various lysosomal hydrolases in ML II fibroblasts after treatment. However, only the α-Gal values were statistically significant, but the WB analysis for this enzyme did not reveal any band in ASO-treated ML II cells.
We also developed a novel antibody for GlcNAc-PT. Preliminary results showed a β-subunit band both in control and patient fibroblasts (unexpected), but in overexpression both WT and del_ex19 constructs presented α/β precursor bands. So, further assays are needed to assess its specificity.
Conclusion: Our ASO-based approach effectively promotes exon 19 skipping. However, this strategy, as far as we have been able to prove, is not able to restore any GlcNAc-PT enzymatic activity. Further validation, including co-localization studies are planned to clarify these findings.
Is exon skipping the key to correct N-acetylglucosamine-1-phosphotransferase deficiency? An antisense oligonucleotide therapeutic approach
Publication . Gonçalves, Mariana; Moreira, Luciana; Encarnação, Marisa; Gaspar, Paulo; Santos, Juliana Inês; Coutinho, Maria Francisca; Prata, Maria João; Omidi, Maryam; Pohl, Sandra; Silva, Frederico; Oliveira, Paula; Matos, Liliana; Alves, Sandra
Introduction: Mucolipidosis II (ML II) is a Lysosomal Storage Disorder caused by N-acetylglucosamine-1-phosphotransferase (GlcNAc-PT) deficiency, which impairs the trafficking of lysosomal hydrolases. Of all ML II mutations, c.3503_3504delTC in GNPTAB exon 19 is the most frequent, making it a good target for a personalized therapy. Here, we explored an innovative therapeutic strategy based on the use of antisense oligonucleotides (ASOs). Previously, in ML II patients’ fibroblasts, we tested ASOs to induce exon 19 skipping in pre-mRNA, successfully generating an in-frame mRNA.
Aims: Now, our aim is to determine whether this in-frame transcript leads to increased GlcNAc-PT levels improving ML II cellular phenotype.
Methodology: First, the GlcNAc-PT activity was measured in fibroblasts by a radioactive assay, but activity levels were similar in ML II and control fibroblasts (treated and non-treated) showing that the assay is not proper to measure endogenous levels. To overcome this, we designed 3 constructs: a WT (full GNPTAB cDNA), a del_ex19 (without the exon 19) and a mutant (with the mutation c.3503_3504delTC) that were transfected in HEK293T cells. Then GlcNAc-PT expression was analyzed by Western Blot (WB).
Additionally, we have measured the activity of several lysosomal hydrolases and evaluated the expression of α-galactosidase A (α-Gal) by WB after ASO treatment of control and patient cells.
To further help in the validation of this therapy we are also generating a novel GlcNAc-PT antibody in rabbits.
Results: Our results demonstrated that HEK293T cells were able to express all the constructs. The WB of both WT and del_ex19 constructs showed bands corresponding to the α/β precursor. However, only the WT construct expressed the β subunit, suggesting that there is no GlcNAc-PT activity in the absence of exon 19. As expected, the c.3503_3504delTC construct showed no expression, with no detectable α/β precursor band.
We also observed a slight increase in the activity of various lysosomal hydrolases in ML II fibroblasts treated with the ASO, particularly 24h and 48h post-treatment. However, only the values relatively to the α-Gal were statistically significant, but the WB analysis using an antibody against this enzyme did not detect any band in ASO-treated ML II fibroblasts.
We also developed a novel antibody for GlcNAc-PT. Preliminary results revealed a band corresponding to the β-subunit in both control and ML II patient fibroblasts (unexpected), but in overexpression assays both WT and del_ex19 constructs presented α/β precursor bands. So, further assays are needed to assess their specificity.
Conclusion: Our ASO-based approach effectively promotes the skipping of exon 19. However, this strategy, as far as we have been able to prove, is not able to restore any GlcNAc-PT enzymatic activity. Further validation, including co-localization studies are planned to clarify these findings.
Do (xeno)estrogens pose a risk to earthworms? Soy isoflavones and estradiol impact gonad structure and induce oxidative stress in Eisenia fetida
Publication . Azevedo, Tiago; Silva-Reis, Rita; Medeiros-Fonseca, Beatriz; Gonçalves, Mariana; Mendes, Gabriel; Roboredo, Marta; Rocha, Maria J.; Peixoto, Francisco; Pinto, Maria de Lurdes; Matos, Manuela; Sousa, João R.; Oliveira, Paula A.; Coimbra, Ana M.
Understanding the impact of endocrine disruptor compounds (EDCs) across a wide range of species is crucial, given their ubiquitous presence. Although invertebrate species lack sex steroid hormone pathways, they exhibit sensitivity to EDCs, which could affect population dynamics. This study assessed reproductive endpoints and oxidative stress parameters in Eisenia fetida following exposure to estradiol and soy isoflavones, resembling the concentrations found in livestock manure. The experiment used artificial soil, as recommended by OECD guidelines (7:2:1 sand, kaolin and peat). Adult specimens were randomly divided into seven groups (n = 11/replicate): one control, three estradiol (156.1, 283.4 and 633.8 μg/kg of dry soil) and three soy isoflavones (113.0, 215.3 and 405.0 mg/kg of dry soil) concentrations. After eight weeks, samples were collected for cytological, histological and biochemical analysis. Offspring development was assessed after 12 additional weeks. Higher estradiol and isoflavone concentrations led to lower germ cell number and increased abnormalities, especially in the seminal vesicles and ovaries. Catalase and peroxidase activities were significantly increased in all treated groups. The exposure did not significantly affect the number of E. fetida offspring. These findings highlight E. fetida’s sensitivity to EDCs at a biochemical and tissue level, suggesting its use as a bioindicator for assessing EDC contamination in soils.
Unidades organizacionais
Descrição
Palavras-chave
, Medical and health sciences ,Medical and health sciences/Medical biotechnology
Contribuidores
Financiadores
Entidade financiadora
Fundação para a Ciência e a Tecnologia, I.P.
Programa de financiamento
Número da atribuição
2022.13676.BD